EcoDrugPlus

Endothelin Receptor Type A

Ensembl ID : ENSPKIG00000016218
Gene Symbol: EDNRA
4 Cross references
263 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSPKIG00000001013
Gene Symbol: EDNRB
3 Cross references
196 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSPKIG00000016285
Gene Symbol: LOC111832936
4 Cross references
263 Possible Orthologues:

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSPKIG00000001147
Gene Symbol: EZH2
2 Cross references
236 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSPKIG00000018119
Gene Symbol: EGFR
3 Cross references
215 Possible Orthologues:

Epidermal Growth Factor Receptor-Like

Ensembl ID : ENSPKIG00000006804
Gene Symbol: LOC111845900
3 Cross references
212 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSPKIG00000020909
Gene Symbol: LOC111852338
3 Cross references
209 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSPKIG00000017523
Gene Symbol: ERBB2
3 Cross references
198 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSPKIG00000007304
Gene Symbol: ERBB2
1 Cross references
198 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSPKIG00000007286
Gene Symbol: ERBB3
3 Cross references
280 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSPKIG00000017737
Gene Symbol: ERBB4
3 Cross references
235 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSPKIG00000015110
Gene Symbol: ERBB4
4 Cross references
235 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).